Hyperliquid Strategies, a pending merged entity involving Nasdaq-listed Sonnet BioTherapeutics and Rorschach I LLC, has filed an S-1 registration statement with the US Securities and Exchange Commission (SEC) to raise up to $1 billion.
Read MoreHyperliquid Strategies, a pending merged entity involving Nasdaq-listed Sonnet BioTherapeutics and Rorschach I LLC, has filed an S-1 registration statement with the US Securities and Exchange Commission (SEC) to raise up to $1 billion.
Read More